Who owns Annexon, Inc. (ANN)? Elite investor 13F holders
2 tracked elite investors reported holding Annexon, Inc as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | ANNEXON INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1514772.00 USD | 265284.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | ANNEXON INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 2620890.00 USD | 459000.000000 | Shares | reduce | Original filing |
| Polen Capital Management | ANNEXON INC | SHARE | 2026-06-30 | 2026-08-04 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.